Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose furmonertinib with or without bevacizumab for EGFR-mutant non-squamous NSCLC with brain metastases
ChiCTR2200063595Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of furmonertinib and bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Overall progression-free survival. Started Sep 2022; status: recruiting.
02
Drugs
furmonertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200063595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063595.